{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T02:12:45Z","timestamp":1775009565837,"version":"3.50.1"},"reference-count":21,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Institutes of Health T32","award":["2T32CA217834-07"],"award-info":[{"award-number":["2T32CA217834-07"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Since 177Lu-DOTATATE was approved for patients with somatostatin receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumors (NETs), tumor flare reactions including increased pain and small bowel obstruction (SBO) have been reported. Retrospective reviews report some success in using corticosteroids for treatment and prophylaxis of tumor flare reactions from 177Lu-DOTATATE. Given that corticosteroids are used in practice to help prevent tumor flare reactions based on limited evidence, we aimed to assess if this practice was efficacious in our patient population. Methods: In this retrospective and single-institution study, we identified adult patients with NETs who were treated with 177Lu-DOTATATE between 1 October 2019 and 31 December 2024; these patients received corticosteroids as prophylaxis for flare reactions due to high burden of disease, significant peritoneal or mesenteric disease, or disease involvement of critical structures as determined by the treating provider. Variables including demographics, diagnosis, treatment history, steroid dosing, and outcomes were collected within a RedCAP database. Results: Forty-six patients were identified as having received corticosteroid prophylaxis to prevent a tumor flare reaction due to 177Lu-DOTATATE. Patients had a median age of 66, and 50% were female. The primary disease site was the small intestine (72%) followed by the pancreas (9%). The majority of patients had World Health Organization (WHO) grade 1 (41%) or WHO grade 2 (35%) diseases. Most patients (83%) received corticosteroids prior to the initiation of 177Lu-DOTATATE, while 17% of patients received corticosteroids due to having a previous tumor flare after 177Lu-DOTATATE administration. Despite corticosteroid prophylaxis, 28% of patients still experienced a tumor flare event, with three patients experiencing multiple tumor flare events. Small bowel obstructions occurred in 7% of patients and increased abdominal pain in 22% of patients. Adverse events (AEs) due to corticosteroids occurred in 28% of patients. Conclusions: Short-course corticosteroid prophylaxis to prevent tumor flare reactions in high-risk patients with neuroendocrine tumors treated with 177Lu-DOTATATE did not appear to decrease the incidence of tumor flare reactions compared to previously reported numbers. Randomized, placebo-controlled trials looking at the use of corticosteroids to prevent tumor flare reactions in patients treated with 177Lu-DOTATATE are needed to fully elucidate the safety and efficacy of corticosteroids used in this setting and to determine the impact on treatment outcomes.<\/jats:p>","DOI":"10.3390\/cancers17213472","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:50:19Z","timestamp":1761785419000},"page":"3472","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of Using Corticosteroid Prophylaxis to Prevent Tumor Flare Reactions During 177Lu-DOTATATE Treatment in Patients with Neuroendocrine Tumors"],"prefix":"10.3390","volume":"17","author":[{"given":"Amanda S.","family":"Cass","sequence":"first","affiliation":[{"name":"Vanderbilt Ingram Cancer Center, Nashville, TN 37232, USA"},{"name":"Department of Medicine, Division of Hematology\/Oncology, Vanderbilt University Medical Center, Nashville, TN 37232, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Skotte","sequence":"additional","affiliation":[{"name":"Vanderbilt Ingram Cancer Center, Nashville, TN 37232, USA"},{"name":"Department of Medicine, Division of Hematology\/Oncology, Vanderbilt University Medical Center, Nashville, TN 37232, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4494-1350","authenticated-orcid":false,"given":"Margaret C.","family":"Wheless","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology\/Oncology, Vanderbilt University Medical Center, Nashville, TN 37232, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2799-663X","authenticated-orcid":false,"given":"Shannon","family":"Stockton","sequence":"additional","affiliation":[{"name":"Vanderbilt Ingram Cancer Center, Nashville, TN 37232, USA"},{"name":"Department of Medicine, Division of Hematology\/Oncology, Vanderbilt University Medical Center, Nashville, TN 37232, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8762-5852","authenticated-orcid":false,"given":"Robert A.","family":"Ramirez","sequence":"additional","affiliation":[{"name":"Vanderbilt Ingram Cancer Center, Nashville, TN 37232, USA"},{"name":"Department of Medicine, Division of Hematology\/Oncology, Vanderbilt University Medical Center, Nashville, TN 37232, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Sultana, Q., Kar, J., Verma, A., Sanghvi, S., Kaka, N., Patel, N., Sethi, Y., Chopra, H., Kamal, M.A., and Greig, N.H. (2023). A Comprehensive Review on Neuroendocrine Neoplasms: Presentation, Pathophysiology and Management. J. Clin. Med., 12.","DOI":"10.3390\/jcm12155138"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11912-021-01029-7","article-title":"Epidemiology, Incidence, and Prevalence of Neuroendocrine Neoplasms: Are There Global Differences?","volume":"23","author":"Das","year":"2021","journal-title":"Curr. Oncol. Rep."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Chauhan, A., Del Rivero, J., Ramirez, R.A., Soares, H.P., and Li, D. (2022). Treatment Sequencing Strategies in Advanced Neuroendocrine Tumors: A Review. Cancers, 14.","DOI":"10.3390\/cancers14215248"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e723","DOI":"10.1093\/oncolo\/oyad093","article-title":"The Mutational, Prognostic, and Therapeutic Landscape of Neuroendocrine Neoplasms","volume":"28","author":"Liu","year":"2023","journal-title":"Oncologist"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/j.jtho.2020.06.021","article-title":"Commonwealth Neuroendocrine Tumour Research Collaboration and the North American Neuroendocrine Tumor Society Guidelines for the Diagnosis and Management of Patients With Lung Neuroendocrine Tumors: An International Collaborative Endorsement and Update of the 2015 European Neuroendocrine Tumor Society Expert Consensus Guidelines","volume":"15","author":"Singh","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"S1511","DOI":"10.21037\/jtd.2017.09.82","article-title":"The role of peptide receptor radionuclide therapy in advanced\/metastatic thoracic neuroendocrine tumors","volume":"9","author":"Bodei","year":"2017","journal-title":"J. Thorac. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Merola, E., and Grana, C.M. (2023). Peptide Receptor Radionuclide Therapy (PRRT): Innovations and Improvements. Cancers, 15.","DOI":"10.3390\/cancers15112975"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Hennrich, U., and Kopka, K. (2019). Lutathera\u00ae: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy. Pharmaceuticals, 12.","DOI":"10.3390\/ph12030114"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nucmedbio.2021.06.006","article-title":"Overcoming nephrotoxicity in peptide receptor radionuclide therapy using [177Lu]Lu-DOTA-TATE for the treatment of neuroendocrine tumours","volume":"102\u2013103","author":"Geenen","year":"2021","journal-title":"Nucl. Med. Biol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1007\/s00259-012-2330-6","article-title":"The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours","volume":"40","author":"Zaknun","year":"2013","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","article-title":"Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): Final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial","volume":"22","author":"Strosberg","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","article-title":"[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2\u20133, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): An open-label, randomised, phase 3 study","volume":"403","author":"Singh","year":"2024","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1200\/JCO.2018.78.5865","article-title":"Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial","volume":"36","author":"Strosberg","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.2967\/jnumed.120.258897","article-title":"Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-DOTATATE","volume":"62","author":"Strosberg","year":"2021","journal-title":"J. Nucl. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"100623","DOI":"10.1016\/j.adro.2020.11.008","article-title":"Lutetium Lu-177 Dotatate Flare Reaction","volume":"6","author":"Salner","year":"2021","journal-title":"Adv. Radiat. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2967\/jnumed.120.242875","article-title":"Risk of Bowel Obstruction in Patients with Mesenteric or Peritoneal Disease Receiving Peptide Receptor Radionuclide Therapy","volume":"62","author":"Strosberg","year":"2021","journal-title":"J. Nucl. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.radonc.2004.12.016","article-title":"Pain flare following external beam radiotherapy and meaningful change in pain scores in the treatment of bone metastases","volume":"75","author":"Chow","year":"2005","journal-title":"Radiother. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.ijrobp.2020.05.007","article-title":"Dexamethasone for the Prevention of a Pain Flare After Palliative Radiation Therapy for Painful Bone Metastases: The Multicenter Double-Blind Placebo-Controlled 3-Armed Randomized Dutch DEXA Study","volume":"108","author":"Westhoff","year":"2020","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_20","first-page":"643","article-title":"Dexamethasone for the prophylaxis of radiation-induced pain flare after palliative radiotherapy for bone metastases\u2014A pilot study","volume":"15","author":"Chow","year":"2007","journal-title":"Support. Care Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"5070","DOI":"10.1210\/endo.136.11.7588243","article-title":"Dexamethasone regulates somatostatin receptor subtype messenger ribonucleic acid expression in rat pituitary GH4C1 cells","volume":"136","author":"Xu","year":"1995","journal-title":"Endocrinology"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/21\/3472\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:58:48Z","timestamp":1761785928000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/21\/3472"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":21,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["cancers17213472"],"URL":"https:\/\/doi.org\/10.3390\/cancers17213472","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,29]]}}}